Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8886940 | 0.78 | ABCG2 (0.53) | ABCG2ALDH1A1MEN1KMT2A | |
| SCHEMBL2864184 | 0.75 | CYP2C19 (0.56) | ABCG2CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL8365595 | 0.75 | ABCG2 (0.50) | ABCG2CLK4CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL30298952 | 0.74 | ABCG2 (0.47) | ABCG2CLK4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16930781 | 0.73 | ABCG2 (0.56) | ABCG2CLK4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1741768 | 0.73 | CLK4 (0.62) | ABCG2CLK4ABCB1TSHRMMP3 | |
| SCHEMBL8842521 | 0.72 | ABCG2 (0.62) | ABCG2CLK4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29961369 | 0.72 | SCN9A (0.47) | ABCG2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL2479265 | 0.70 | MMP3 (0.52) | ABCG2ABCB1ABCC1ALDH1A1TSHR | |
| SCHEMBL10608725 | 0.68 | ABCG2 (0.44) | ABCG2CLK4CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101133038-B | HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines | TIBOTEC PHARM LTD | 2012-06-27 | — | — | CN | disclosed |
| CN-101133038-B | HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines | TIBOTEC PHARM LTD | 2012-06-27 | — | — | CN | disclosed |
| US-8119801-B2 | HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-02-21 | — | — | US | disclosed |
| US-8119801-B2 | HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-02-21 | — | — | US | disclosed |
| WO-2011135578-A1 | COMPOSITION COMPRISING CHITIN AND TINOSPORIN FOR USE IN THE TREATMENT OF VIRAL DISEASES | BALAR CHETAN (IN) | 2011-11-03 | — | — | WO | disclosed |
| EP-1858861-B1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | TIBOTEC PHARM LTD (IE) | 2010-07-07 | — | — | EP | disclosed |
| US-20100121060-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-05-13 | — | — | US | disclosed |
| US-20080214588-A1 | Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines | TIBOTEC BVBA (BE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214588-A1 | Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines | TIBOTEC BVBA (BE) | 2008-09-04 | — | — | US | disclosed |
| CN-101133038-A | HIV inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines | TIBOTEC PHARM LTD (IE) | 2008-02-27 | — | — | CN | disclosed |
| EP-1858861-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1858861-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094930-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214588-A1 | Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines | RTF2, MCM6, SAMHD1 | ABCG2 529/4885CLK4 756/4885CYP1A2 802/4885 |
| US-20100121060-A1 | HIV INHIBITING 2-(4-CYANOPHENYL)-6-HYDROXYLAMINOPYRIMIDINES | RTF2, MCM6, CDK6 | ABCG2 730/4885CLK4 834/4885CYP1A2 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.